Press Releases
OncoNano Announces Appointment of Brent Sorrells as Chief Operating Officer
DALLAS, Texas – November 17, 2025 – OncoNano Medicine, Inc. (“OncoNano”) announces the appointment of Brent Sorrells as Chief Operating Officer. Bringing more than two decades of experience in product development, strategic operations and commercial execution across the biotechnology industry, Mr. Sorrells will help drive OncoNano’s next phase of growth and operational excellence.
“Brent joins OncoNano at a pivotal inflection point as we advance our first polymer drug conjugate from our ON-BOARD™ micelle platform into IND-enabling studies and continue development of ONM-501, our dual-acting STING agonist,” said Kartik Krishnan, MD, PhD, Chief Executive Officer of OncoNano Medicine. “Brent’s extensive operational and leadership experience will be instrumental as we advance our strategic priorities and continue to execute on key growth milestones.”
Mr. Sorrells most recently served as Vice President of Product Development and Strategy at Allakos, Inc., until its acquisition in May 2025. During his time at Allakos he held various leadership roles in clinical operations. Mr. Sorrells previously held senior roles within the clinical team at ZS Pharma. He has also worked for and served as board chair of a nonprofit business incubator for tech startups. Mr. Sorrells earned a Bachelor of Science in Biology and a Master of Business Administration from the University of North Texas.
“OncoNano’s vision to redefine how cancer is treated through targeted delivery of medicines to improve their therapeutic index is truly compelling,” said Brent Sorrells. “The science, the team and the opportunity to make a real difference for patients make this an incredibly exciting time to come on board.”
About OncoNano Medicine
OncoNano Medicine, Inc. is a clinical-stage biotechnology company working to transform cancer therapeutics with its proprietary nanotechnology platform. OncoNano's polymeric micelle platform is designed to leverage a universal tumor target, namely pH, to precisely deliver anti-cancer payloads to the tumor microenvironment. Our product candidates are designed to improve the pharmacokinetic and pharmacodynamic properties of various payloads from small molecules to large biologics through encapsulation and localized tumor targeting. OncoNano is utilizing its polymeric micelle technology to generate a robust oncology pipeline to support novel therapeutic development for patients with high unmet medical needs. Learn more about our platform and pipeline at www.OncoNano.com.
Contacts
OncoNano Medicine
LA Communications
Lauren Arnold
617-694-5387
OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at AACR-NCI-EORTC
Results show durable responses and prolonged stable disease in patients with advanced solid tumors; combination with Libtayo® (cemiplimab) yields complete responses in cutaneous squamous cell carcinoma
DALLAS, Texas – October 27, 2025 – OncoNano Medicine, Inc. (“OncoNano”) announced encouraging first-in-human results from Part 1 of its Phase 1 ON-5001 trial evaluating ONM-501, a dual-acting STING agonist, as monotherapy and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, in patients with advanced solid tumors and lymphomas. The findings were shared during a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.
ONM-501 is designed to activate the STING pathway and stimulate both innate and adaptive immune responses within the tumor microenvironment. By linking a cyclic dinucleotide (cGAMP) to a proprietary polymer, ONM-501 prolongs STING activation and overcomes key limitations of earlier STING agonists. In preclinical models, this approach produced durable anti-tumor responses without triggering systemic inflammation, an effect now supported by emerging clinical results.
In the dose-escalation and dose-finding study, ONM-501 was well tolerated and demonstrated early signs of clinical benefit. Among 39 patients treated (15 with ONM-501 monotherapy and 24 in combination with cemiplimab), no dose-limiting toxicities were observed, and the most common adverse events were mild fatigue and injection-site reactions. Systemic interferon-γ levels remained within normal limits across all cohorts.
In the monotherapy arm, one patient achieved an objective response and three patients had prolonged stable disease, including a case of recurrent, immunotherapy-refractory uveal melanoma with disease control lasting over one year (390 days). In the combination arm, five patients experienced objective responses, including two complete in patients with cutaneous squamous cell carcinoma (cSCC).
“These data provide the first clinical evidence that sustained STING activation through our proprietary polymer conjugate can drive meaningful immune responses in solid tumors,” said Kartik Krishnan, MD, PhD, Chief Executive Officer of OncoNano Medicine. “The safety profile and emerging efficacy signals, particularly in patients with advanced cutaneous malignancies, highlight the potential of ONM-501 to expand the reach of STING-based immunotherapy.”
Part 2 of the ON-5001 study (NCT06022029) is now open and enrolling patients with advanced basal cell carcinoma, cutaneous squamous cell carcinoma and melanoma.
About ONM-501
ONM-501 is a dual-activating agonist of the stimulator of interferon genes (“STING”) pathway composed of cGAMP (the endogenous activator of STING) linked to a proprietary pH-activated polymer (the OMNI™ polymer). ONM-501 is presently being studied in a Phase 1 clinical trial (ON-5001). In preclinical models, the dual activation of STING by ONM-501 has been shown to lead to a direct anti-tumor effect, as well as leading to an anti-tumor immune response over an extended period of time. Development of ONM-501 was funded in part by the Cancer Prevention and Research Institute of Texas.
About OncoNano Medicine
OncoNano Medicine, Inc. is a clinical-stage biotechnology company working to transform cancer therapeutics with its proprietary nanotechnology platform. OncoNano's polymeric micelle platform is designed to leverage a universal tumor target, namely pH, to precisely deliver anti-cancer payloads to the tumor microenvironment. Our product candidates are designed to improve the pharmacokinetic and pharmacodynamic properties of various payloads from small molecules to large biologics through encapsulation and localized tumor targeting. OncoNano is utilizing its polymeric micelle technology to generate a robust oncology pipeline to support novel therapeutic development for patients with high unmet medical needs. Learn more about our platform and pipeline at www.OncoNano.com.
Contacts
OncoNano Medicine
LA Communications
Lauren Arnold
617-694-5387
OncoNano Medicine Announces Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
DALLAS, Texas – October 15, 2025 – OncoNano Medicine, Inc. (“OncoNano”) today announced a late-breaking research poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Boston, Massachusetts, October 22 - 26, 2025. Details on the posters are below.
Presentation Details
Title: Results from part-1 of ON-5001: a multi-center, dose escalation and dose finding Phase 1 trial of ONM-501, a dual-acting STING agonist, alone or in combination with cemiplimab in patients with solid tumors and lymphoma
Session: Poster Session A
Date & Time: Thursday, October 23, 12:30-4 pm
About ONM-501
ONM-501 is a dual-activating agonist of the stimulator of interferon gene (“STING”) pathway composed of cGAMP (the endogenous activator of STING) linked to a proprietary pH-activated polymer (the OMNI™ polymer). ONM-501 is presently being studied in a Phase 1 clinical trial (ON-5001). In preclinical models, the dual activation of STING by ONM-501 has been shown to lead to direct anti-tumor effect, as well as leading to an anti-tumor immune response over an extended period of time. Development of ONM-501 was funded in part by the Cancer Prevention and Research Institute of Texas.
About OncoNano Medicine
OncoNano Medicine, Inc. is a clinical-stage biotechnology company working to transform cancer therapeutics with its proprietary nanotechnology platform. OncoNano's polymeric micelle platform is designed to leverage a universal tumor target, namely pH, to precisely deliver anti-cancer payloads to the tumor microenvironment. Our product candidates are designed to improve the pharmacokinetic and pharmacodynamic properties of various payloads from small molecules to large biologics through encapsulation and localized tumor targeting. OncoNano is utilizing its polymeric micelle technology to generate a robust oncology pipeline to support novel therapeutic development for patients with high unmet medical needs. Learn more about our platform and pipeline at www.OncoNano.com.
Contacts
OncoNano Medicine
LA Communications
Lauren Arnold
617-694-5387